Having 60 starters in the trial is a reasonable number, to get an indication of its effectiveness especially with information gained from the bio markers. The delay and possible additional research may enhance a positive result. As a guess this article was formulated by Kempler not David Stamler because of the lack, of additional information shareholders would appreciate.
Ann: Expanded ATH434 Phase 2 Clinical Development Program, page-10
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
